1. Home
  2. MHH vs IMMP Comparison

MHH vs IMMP Comparison

Compare MHH & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mastech Digital Inc

MHH

Mastech Digital Inc

HOLD

Current Price

$6.26

Market Cap

72.6M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.47

Market Cap

76.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHH
IMMP
Founded
1986
1987
Country
United States
Australia
Employees
N/A
51
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
76.6M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
MHH
IMMP
Price
$6.26
$0.47
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
22.0K
1.2M
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$191,371,000.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
$9.07
N/A
P/E Ratio
$122.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$0.29
52 Week High
$8.37
$3.53

Technical Indicators

Market Signals
Indicator
MHH
IMMP
Relative Strength Index (RSI) 44.97 41.99
Support Level $5.53 $0.42
Resistance Level $7.11 $1.05
Average True Range (ATR) 0.42 0.03
MACD -0.11 0.02
Stochastic Oscillator 43.38 39.47

Price Performance

Historical Comparison
MHH
IMMP

About MHH Mastech Digital Inc

Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: